AI Article Synopsis

  • The burden of stroke varies by region due to differences in comorbid conditions and ethnicity, as influenced by genomewide variations acting as proxies for these factors.
  • An integrated analysis of stroke prevalence and mortality rates across 204 countries from 2009 to 2019 reveals distinct ethnogeographic trends, showing that metabolic risk is higher in America and Europe while systolic blood pressure is a major risk in Asia and Africa.
  • Identifying unique genetic risk variants specific to populations can lead to targeted prevention strategies for stroke based on regional and ethnic risk factors.

Article Abstract

Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398864PMC
http://dx.doi.org/10.7554/eLife.94088DOI Listing

Publication Analysis

Top Keywords

comorbid conditions
20
risk variants
16
stroke comorbid
16
risk
12
stroke
9
genetic risk
8
variants stroke
8
burden stroke
8
gwas risk
8
risk drivers
8

Similar Publications

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide.

View Article and Find Full Text PDF

The Genetics of Neurodevelopmental Disorders Lab in Padua provided a new intellectual disability (ID) Panel challenge for computational methods to predict patient phenotypes and their causal variants in the context of the Critical Assessment of the Genome Interpretation, 6th edition (CAGI6). Eight research teams submitted a total of 30 models to predict phenotypes based on the sequences of 74 genes (VCF format) in 415 pediatric patients affected by Neurodevelopmental Disorders (NDDs). NDDs are clinically and genetically heterogeneous conditions, with onset in infant age.

View Article and Find Full Text PDF

Background: Neurofilament Light Chain (NfL) is a blood biomarker of axonal injury and neurodegeneration that can be used in a variety of neurological disorders. Despite the potential clinical use of plasma NfL across multiple neurological disorders, there is increasing evidence that underlying comorbidities such as renal impairment associated with chronic kidney disease (CKD) and cardiovascular diseases can increase NfL concentrations. The objective of this study was to determine the relationship between plasma NfL concentrations and renal function (CKD staging) in individuals without known neurological conditions.

View Article and Find Full Text PDF

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.

Int J Cancer

January 2025

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.

The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948).

View Article and Find Full Text PDF

Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study.

Hum Vaccin Immunother

December 2025

Medical Specialities and Public Health Department, Area of Preventive Medicine and Public Health, Rey Juan Carlos University, Alcorcón, Madrid, Spain.

Pneumococcal disease is a leading cause of morbidity and mortality worldwide. From 2016 to 2022, 358,603 hospitalized patients were identified as having pneumococcal disease. The overall annual hospitalization rate was 108.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!